Emergency Medicine

HIV / AIDS

Medical News

Primary Care

Surgery

Home » Lupus, Medical News

ImmuPharma Announces Final Results Of PhaseIIb Study Of LUPUZOR™ In Lupus

Submitted by MedicalReplies on Monday, 23 November 2009No Comment

ImmuPharma PLC announced the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.

The rest is here:
ImmuPharma Announces Final Results Of PhaseIIb Study Of LUPUZOR™ In Lupus

You may also like:

Leave your response!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.

*
To prove you're a person (not a spam script), type the security word shown in the picture.
Anti-spam image